Related Experiment Video
Updated: Aug 5, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Association between resection margin and local recurrence in the treatment of primary squamous cell vulvar carcinoma
Hein Hanna1, Gasimli Khayal2, Rödel Claus1
1Department of Radiotherapy and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
Objective:
Our aim was to assess the potential correlation between resection-free margin and local recurrence in the treatment of squamous cell vulvar carcinoma (SCC).
Methods:
Seventy-five patients with primary SCC of the vulva and adequately follow-up that were operated in our university hospital between January 2008 to December 2018, were retrospectively evaluated with focus on resection-free margin and its impact on local recurrence. Several prognostic factors were analysed for possible correlation.
Results:
Median patient age and follow-up was 62.8 years and 57.4 months, respectively. Among all patients, 27 (36%) local recurrences were documented, for a median local recurrence-free survival (LRFS) of 68.1 months for patients resected R0 and 65.6 months for those initially R1 resected (p=0.750). There was also no statistically significant difference (p=0.750) when evaluating the LRFS relative to the absence or not of inguinal lymph node involvement, although there was a numerical difference of approximately 17 months (73.9 vs. 57.3 months). For initially R0 resected patients, no significant influence of the resection-free margin in millimeters on LRFS was noted for a median of 58.4 versus 57.3 months for patients with a free margin of 0.1-3 mm and those with a free margin of >3 mm, respectively (p=0.800). Eleven patients received adjuvant chemoradiotherapy, all for nodal inguinal involvement. Among them, 5 patients developed recurrence, while the other 6 remained free of disease.
Conclusion:
The extend of resection-free margin does not appear to adversely affect LRFS suggesting that smaller margins could be applied to minimize morbidity without compromising local control.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Varicose Veins II: Diagnostic Studies and Interprofessional Care

